z-logo
Premium
Persistence of seropositivity among persons vaccinated for hepatitis A during infancy by maternal antibody status: 15‐year follow‐up
Author(s) -
Spradling Philip R.,
Bulkow Lisa R.,
Negus Susan E.,
Homan Chriss,
Bruce Michael G.,
McMahon Brian J.
Publication year - 2016
Publication title -
hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.488
H-Index - 361
eISSN - 1527-3350
pISSN - 0270-9139
DOI - 10.1002/hep.28375
Subject(s) - medicine , vaccination , hepatitis a vaccine , hepatitis a , hepatitis a virus , age groups , persistence (discontinuity) , pediatrics , immunology , demography , hepatitis , virus , geotechnical engineering , sociology , engineering
The effect of passively transferred maternal antibody to hepatitis A virus (anti‐HAV) on the duration of seropositivity after hepatitis A vaccination during infancy and early childhood is unclear. We obtained levels of anti‐HAV at intervals through age 15‐16 years among three groups of Alaskan Native children who initiated a two‐dose inactivated hepatitis A vaccination series at ages 6 months (group 1), 12 months (group 2), and 15 months (group 3), each group randomized according to maternal anti‐HAV status. Seropositivity (anti‐HAV ≥20 mIU/mL) 30 years after the second vaccine dose among the three groups was predicted using a random effects model. One hundred eighty‐three children participated in the study; follow‐up did not differ significantly by vaccine group or maternal anti‐HAV status. Although the frequency of seropositivity among all participants through age 10 years was high (100% among groups 2 and 3 and >90% among group 1), there was a decrease thereafter through age 15‐16 years among group 1 children, who initiated vaccination at age 6 months (50%‐75%), and among maternal anti‐HAV‐positive children in groups 2 and 3 (67%‐87%), who initiated vaccination at ages 12 months and 15 months, respectively. Nonetheless, the model indicated that anti‐HAV seropositivity should persist for ≥30 years after vaccination in 64% of all participants; among those seropositive at age 15‐16 years, 84% were predicted to remain so for ≥30 years. Conclusion : Most children vaccinated during early childhood available for sampling maintained seropositivity through age 15‐16 years; however, seropositivity was less frequent among those starting vaccination at age 6 months and among maternal antibody‐positive participants who started vaccination at age 12 months or 15 months; overall, our findings support current vaccine recommendations and continued follow‐up of this cohort. (H epatology 2016;63:703–711)

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom